What should be done for a patient with ulcerative colitis and primary sclerosing cholangitis who has received 8 weeks of oral corticosteroids and is currently on adalimumab (Humira) but shows inadequate response?

Switch from Adalimumab to a More Effective Advanced Therapy

You need to stop Humira and switch to a different advanced therapy immediately—after 8 weeks of steroids without achieving steroid-free remission, continuing adalimumab is not appropriate. 1, 2

Why Adalimumab Has Failed

Your situation represents corticosteroid-dependent or corticosteroid-refractory UC, which mandates treatment escalation. The Toronto and BSG guidelines are clear: patients should be evaluated for lack of response to corticosteroids within 2 weeks, and if no adequate response occurs, advanced therapy should be started or switched 1, 2. After 8 weeks on steroids (Cortiment/budesonide), you've exceeded this window significantly—prolonged corticosteroid use is associated with significant adverse effects and is explicitly not recommended for maintenance 1, 3.

The FDA label confirms that Humira should be discontinued in UC patients without evidence of clinical remission by 8 weeks (Day 57) of therapy 4. You're well past this point.

Best Next Step: Switch to Higher-Efficacy Biologic

For patients with prior anti-TNF exposure (like you on Humira/adalimumab), the 2024 AGA guidelines recommend switching to a higher-efficacy medication 5. The most recent evidence shows:

First-Line Options After Adalimumab Failure:

• Infliximab (another anti-TNF, but IV with potentially better pharmacokinetics)
• Upadacitinib (JAK inhibitor, highest efficacy in anti-TNF-exposed patients)
• Tofacitinib (JAK inhibitor, FDA-approved specifically after TNF failure)
• Ustekinumab (IL-12/23 inhibitor)

The 2020 AGA guidelines specifically state: "In adult outpatients with moderate-severe UC who have previously been exposed to infliximab, particularly those with primary non-response, the AGA suggests using ustekinumab or tofacitinib, rather than vedolizumab or adalimumab" 6. While you were on adalimumab (not infliximab), the principle of switching drug classes after anti-TNF failure applies.

Why Not Just Dose-Escalate Adalimumab?

While dose escalation of adalimumab to weekly dosing is possible 7, you've already been on therapy for an extended period with inadequate response. Research shows that annual loss of response for adalimumab in UC is 13-23%, with dose escalation regaining clinical benefit in only 52% of patients 8. Given your concurrent PSC, switching to a different mechanism is more prudent.

Special Consideration: Your PSC Complicates Things

Your concurrent PSC-IBD represents a distinct phenotype that may respond differently to therapies 9, 10. Recent real-world data shows:

• Infliximab and vedolizumab appear equally effective in PSC-IBD vs IBD alone
• Ustekinumab showed significantly lower early clinical response in PSC-IBD patients (43% vs 77%) 9
• Vedolizumab and adalimumab have shown modest biochemical improvements in PSC 10

This evidence suggests infliximab or vedolizumab may be preferable over ustekinumab in your specific case.

Specific Recommendation Algorithm

Step 1: Immediate Action

• Stop prolonged steroid use (you're at 8 weeks, well beyond the 2-week evaluation window)
• Check adalimumab drug levels and anti-drug antibodies if available—this helps determine if you have pharmacokinetic failure vs true biologic failure

Step 2: Choose Next Therapy Based on:

If you're anti-TNF naive (no prior infliximab):

• First choice: Infliximab (IV, 5mg/kg at weeks 0,2,6, then every 8 weeks)
  • Can combine with thiopurine (azathioprine/6-MP) for enhanced efficacy 1, 6
  • Particularly effective in PSC-IBD 9

If you want to avoid another anti-TNF:

• Second choice: Vedolizumab (gut-selective, 300mg IV at weeks 0,2,6, then every 8 weeks)
  • Equally effective in PSC-IBD 9
  • Lower systemic immunosuppression

If you need highest efficacy and accept higher risk:

• Third choice: Upadacitinib (JAK inhibitor, 45mg daily for 8 weeks induction, then 15-30mg daily)
  • Highest efficacy in anti-TNF-exposed patients 5
  • BUT: FDA black box warnings for thromboembolism and mortality at higher doses 6
  • Caution: Lower response rates in PSC-IBD for IL-12/23 pathway 9

Step 3: Steroid Taper

• Begin taper only after new biologic is loaded (weeks 0,2,6 for IV agents)
• Taper over 6-8 weeks 3, 2

Step 4: Combination Therapy

• Consider adding thiopurine (azathioprine or 6-MP) if using infliximab 1, 6
• The 2020 AGA guidelines suggest combination therapy over monotherapy for anti-TNF agents 6

Common Pitfalls to Avoid

1. Don't continue steroids beyond 2 weeks without response 1, 2—you're already at 8 weeks
2. Don't stay on failed adalimumab 4—the FDA label is explicit about discontinuation at 8 weeks
3. Don't choose ustekinumab as first switch in PSC-IBD—the data shows lower response rates 9
4. Don't forget your PSC surveillance—you need ongoing cholangiocarcinoma screening per BSG guidelines 11

Bottom Line

Switch to infliximab (with or without thiopurine) or vedolizumab immediately while tapering your steroids. These have the best evidence in PSC-IBD and represent appropriate escalation after adalimumab failure. If these fail, upadacitinib or tofacitinib are next-line options, though with more safety considerations.